Contributor(s): Debra Gordon, MS; Dr. Shayna Sandhaus, PhD

1 Overview

Summary and Quick Facts

  • Recent data estimate the overall prevalence of depression at about 11.1% of the American population, or nearly 35 million individuals. And predictive models suggest that up to 50% of the population will experience at least one episode of depression during their lives.
  • Life Extension® acknowledges and appreciates the complex nature of depression and advocates a comprehensive management strategy that includes proactive lifestyle changes, behavioral therapy, hormone restoration and targeted nutritional support to complement conventional antidepressant treatment and balance brain chemistry holistically.
  • Conventional medicine relies heavily on psychoactive drugs that manipulate brain chemistry to treat the underlying causes of depression. Alternative treatment strategies such as behavioral therapy, hormone restoration and targeted natural interventions, including B vitamins and L-tryptophan, may complement conventional treatment to help alleviate symptoms of depression.

What is Depression?

Depression is a psychological disorder characterized by negative feelings that can range from unhappiness to overwhelming despair. Depression can be categorized, using defined clinical guidelines, into several forms including major depressive disorder, dysthymia, psychotic depression, and postpartum depression, among others.

Depression can be caused by a host of factors; unfortunately, conventional medicine relies heavily on psychoactive drugs that manipulate brain chemistry to treat the underlying causes of depression. Fortunately, alternative treatment strategies such as behavioral therapy, hormone restoration, and targeted natural interventions, including B-vitamins and L-tryptophan, may complement conventional treatment to help alleviate symptoms of depression.

What are the Risk Factors for Depression?

  • Conventional risk factors
    • Genetics
    • Early life trauma
    • Lack of meaningful social contact
    • Comorbid conditions such as HIV/AIDS, heart disease, and cancer
  • Biological risk factors
    • Hormonal imbalances
    • Nutritional insufficiencies and deficiencies
    • Oxidative stress and mitochondrial dysfunction
    • Insulin resistance and chronic inflammation

What are the Signs and Symptoms of Depression?

  • Consistent feelings of sadness, anxiety, or emptiness
  • Loss of interest in activities once enjoyed
  • Restlessness, irritability
  • Feeling hopeless
  • Feeling worthless or guilty; suicidal thoughts may occur
  • Disturbed sleep patterns
  • Fatigue
  • Change in eating habits; loss of appetite or overeating
  • Difficulty concentrating, remembering details, or making decisions

Note: A diagnosis of clinical depression must include at least five of these symptoms, and at least one of the first two on the list must be present.

What are Conventional Medical Treatments for Depression?

  • Antidepressants such as selective serotonin reuptake inhibitors (SSRIs) (eg, Prozac), serotonin and norepinephrine reuptake inhibitors (SNRIs) (eg, Cymbalta), and others
  • Cognitive-behavioral therapy
  • Electroconvulsive therapy for severe cases

What are Alternative or Emerging Therapies for Depression?

  • Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate brain nerve cells and is FDA-approved to treat depression in people who have not responded to medication.
  • Hormone restoration therapy (thyroid hormones and/or sex hormones)
  • Light therapy for seasonal affective disorder

What Dietary and Lifestyle Changes Can Be Beneficial for Depression?

  • Regular exercise
  • Eat a healthy, balanced diet—the Mediterranean diet has been shown to reduce mood disorders

What Natural Interventions May Be Beneficial for Depression?

  • B-vitamins. Low levels of the B-vitamins folate and vitamins B6 and B12 have been linked with mood and depression.
  • Omega-3 fatty acids. Omega-3 fatty acids have a wide variety of health benefits; they have been shown to improve mood and symptoms of depression.
  • Melatonin. Low melatonin levels have been linked to depression. Supplementation has been shown to be effective in improving sleep and symptoms of depression.
  • Magnesium. Magnesium is an essential cofactor in many bodily processes. Supplementation may be helpful for treating depressive symptoms.
  • L-tryptophan. L-tryptophan is an amino acid that is essential for serotonin synthesis. Acute tryptophan depletion can cause depression.
  • S-adenosylmethionine (SAMe). SAMe is a methyl donor involved in the synthesis of hormones and neurotransmitters. Combination therapy with SAMe and an SSRI showed improved response and remission compared to the SSRI with placebo.
  • N-acetylcysteine (NAC). NAC is a powerful antioxidant and a precursor to glutathione. Studies showed it to be a safe and effective adjuvant treatment for bipolar disorder.
  • Saffron. Saffron helps modulate serotonin and has neuroprotective activity. Several clinical trials have demonstrated its anti-depressive effects.
  • Curcumin. Curcumin is a polyphenol derived from turmeric. It can positively influence mood, and combination therapy with curcumin and an antidepressant was more effective than the drug alone.
  • Probiotics. Probiotics have been shown to improve behaviors and symptoms related to anxiety, stress, and depression.
  • Other natural interventions that may help people with depression include vitamins C, D, and E, coffee and green coffee extract, inositol, St. John’s wort, and many others.

2 Introduction

Depression is a state of psyche characterized by a spectrum of negative feelings ranging in scope from minor unhappiness to overwhelming despair. Though generally associated with emotional or psychological symptoms, depression can be accompanied by severe pain or other physical symptoms as well; depression is capable of dramatically influencing the lives of those it affects.

Recent data estimate the overall prevalence of depression at about 11.1% of the American population, or nearly 35 million individuals,1 and predictive models suggest that up to 50% of the population will experience at least one episode of depression during their lives.2

The framework underlying the pathogenesis of depression is complex and variable among individuals; both psychological and biological factors influence a person’s state of mind at any given time. For example, emergent research links depression with several metabolic phenomena, including inflammation, insulin resistance, and oxidative stress. Intriguing preliminary data also suggest that mitochondrial dysfunction plays a previously unappreciated role in depression. Moreover, the role of hormones in depression is considerable, including stress hormones (glucocorticoids) and sex hormones (testosterone, estrogen). Many people affected by depression may be suffering from hormonal imbalances that are significantly contributing to their symptoms.3

The mainstream medical establishment relies heavily uponpsychoactive drugs that manipulate brain chemistry as the frontline treatment.4 Unfortunately, the success rate of pharmacologic intervention for depression is a mere 50% or less and these medications are fraught with potential side effects, including a proclivity to increase suicidal ideation with some antidepressant drugs.5

Life Extension, on the other hand, acknowledges and appreciates the complex nature of depression and advocates a comprehensive management strategy that includes proactive lifestyle changes, behavioral therapy, hormone restoration, and targeted nutritional support to complement conventional antidepressant treatment and balance brain chemistry holistically.

3 Types of Depression and Associated Symptoms

Although depression is a clearly defined disorder with mental and physical symptoms, unlike other disorders, doctors cannot diagnose it using a blood panel or other form of lab test. Instead, they use carefully developed clinical guidelines as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM).

Depression is distinguished into various forms. The most common are major depressive disorder and dysthymic disorder.

Major Depressive Disorder (Major Depression)

Major depressive disorder can be very disabling, preventing the patient from functioning normally. A combination of symptoms sabotages the patient’s ability to sleep, study, work, eat, and enjoy formerly pleasurable activities. Some people may experience only a single episode, while others experience recurrent episodes.

Dysthymic Disorder (Dysthymia)

Dysthymia, also known as chronic mild depression, lasts longer than two years. Symptoms are not disabling or as severe as those of major depression, however the patient finds it difficult to function normally and does not feel well. A person with dysthymia may also experience periods of major depression.

Psychotic Depression

Psychotic depression is a severe depressive illness that includes hallucinations, delusions, or withdrawal from reality.

Postpartum Depression (Postnatal Depression)

Postpartum depression, also known as postnatal depression (PND), affects 10% to 15% of all women after giving birth. This is not to be confused with the “baby blues,” which a mother may feel briefly after giving birth. The development of a major depressive episode within a few weeks of giving birth likely indicates PND. Sadly, many of these women go undiagnosed and suffer for long periods without treatment and support.

Seasonal Affective Disorder (SAD)

The incidence of SAD increases along with the distance from the equator. A person who develops a depressive illness during the winter months with symptoms that go away during spring or summer may have SAD. Accumulating evidence points to vitamin D deficiency as a contributing factor in SAD and in other forms of depression.6

Bipolar Disorder (Manic-Depressive Illness)

A patient with bipolar disorder experiences (oftentimes extreme) highs (mania) and lows (depression) in mood. The frequency at which an individual reverts from mania to depression, and vice-versa, determines where they lie on the bipolar spectrum—a diagnostic tool used to measure the severity of bipolar disorder.

4 Diagnosing Depression

A diagnosis of clinical depression requires that the patient experience at least five of the nine symptoms below, as described by the DSM, for most of the day, nearly every day, for at least two weeks. One of the symptoms must be either a constant feeling of sadness, anxiety, and emptiness, or loss of interest in formerly pleasurable activities.

If any of these symptoms affects your relationships and your ability to function at home or work, consult with a health care practitioner qualified to assess and treat depression.

Emotional Symptoms

  • Constant or transient feelings of sadness, anxiety, and emptiness
  • Feeling restless; may experience irritability
  • Feeling hopeless
  • Feeling worthless or guilty for no reason; suicidal thoughts may occur
  • Loss of interest in activities or hobbies once enjoyed; may lose interest in sex

Physical Symptoms

  • Disturbed sleep patterns; may sleep too little or too much
  • Low energy; fatigue
  • Significant weight loss or gain due to a change in eating habits; either loss of appetite or eating too much
  • Difficulty concentrating, remembering details, or making decisions

5 Causes of Depression

Research spanning the last 20 to 30 years has examined a range of influences that contribute to depression. These include genetics, brain chemistry, early life trauma, negative thinking, one’s personality and temperament, stress, and difficulty relating to others.7 Moreover, emerging scientific research suggests that metabolic phenomenon such as inflammation, oxidative stress, and hormonal imbalances can cause or exacerbate depression as well.8,9

Impaired Stress Response

When a person experiences stress—whether it’s physical or emotional, internal or external—the body copes through a complex system of adaptive reactions. This response involves the release of glucocorticoids, or stress hormones, which stimulate adaptive changes throughout the body.

A stress response is designed to help us confront or escape danger by redirecting blood flow to the muscles, dilating the pupils, inhibiting digestion, and releasing stored fatty acids and glucose (blood sugar) to be used by the muscles. This process is known as the fight-or-flight response.

The fight-or-flight response originates in the brain. When the hypothalamus, the brain’s “control tower,” perceives a threat, it sends chemical signals to the brain’s pituitary gland, also known as the master hormone gland. The pituitary gland then sends chemical signals to the adrenal glands, which sit atop the kidneys. The adrenal glands then release the stress hormone cortisol, which triggers many of the physiological responses to danger.

Almost all animals share the fight-or-flight response, as it is paramount for survival. Although we were designed to undergo this response on only an occasional basis, modern humans cope with relentless stress. Such things as financial worries, deadline pressures at work or school, emotional challenges, excessive caloric intake, poor diet, obesity, inactivity, and environmental toxins chronically activate the hypothalamic-pituitary-adrenal axis, keeping us in a perpetual fight-or-flight response. The result is an increased rate of cardiovascular disease, diabetes, and mood disorders such as depression and anxiety.

The relationship between chronic stress, depression, and anxiety is complex, but incredibly powerful. For instance, the chronic elevation of glucocorticoids (primarily cortisol) caused by chronic stress actually changes the physical structure of the brain.

Chronic exposure to glucocorticoids shifts dendrites, the branches of neurons that receive signals from other neurons, into less functional patterns. Research links this phenomenon with alterations in mood, short-term memory, and behavioral flexibility.10 Glucocorticoids blunt the brain’s sensitivity to serotonin, the mood-regulating neurotransmitter most often associated with depression.11,12 Chronic stress also increases one’s susceptibility to neuronal damage and impairs neurogenesis, the process by which new neurons are “born.”10

Interestingly, emerging research suggests that drugs used to treat anxiety and depression may stabilize mood not only by acting on neurotransmitters, but also by regulating the brain’s receptors for stress hormones.13 These new findings strongly support the importance of controlling the stress response in order to alleviate mood disorders. Indeed, several genetic and epidemiological studies have linked excessive stress, and the inability to adapt efficiently to stress, with increased rates of anxiety and depression.14-16

Fortunately, a number of relaxation techniques and coping styles can improve depression, further emphasizing the role of stress in depression. These approaches include Mindfulness-Based Stress Reduction,17 meditation,18 biofeedback,19 progressive muscle relaxation20 and an integrative health approach that combines relaxation, nutrition, and exercise.21

Recent studies suggest some of these techniques influence genetic activity regulating depression.20 Brain imaging techniques show meditation significantly affects neurotransmitter levels and the activity of various parts of the brain that facilitate relaxation.18

Traumatic Events and Post-Traumatic Stress Disorder

Research establishes that trauma, such as the sudden loss of a family member, sexual abuse, or war-related traumas, contributes significantly to prolonged periods of depression. The effects are more pronounced when the trauma occurs in childhood; childhood trauma can considerably alter the structure and function of the brain, increasing susceptibility to depression and anxiety later in life.22

Social Network and Personal Relationships

Lack of meaningful social contact with others has been linked to depression, while evidence increasingly shows that close personal relationships and social networks positively affect mood and health.23 Loving relationships, social connection and support, work-related passion and recognition, and a good marriage help prevent depression.24,25 Interestingly, it also has been shown that while a good marriage benefits both men and women, it seems to be more important for men from an overall health standpoint.

Neurotransmitter Imbalances

Magnetic resonance imaging (MRI) shows that the areas of the brain that orchestrate thinking, sleep, mood, appetite, and behavior function abnormally in depressed patients compared to non-depressed individuals. In addition, an imaging technique called single-photon emission computed tomography (SPECT) shows changes in brain blood flow and neurotransmitter activity in the depressed person’s brain.26,27 Although imaging technology can identify neurotransmitter imbalances, it cannot reveal why depression has occurred.

Comorbid Conditions

Depression is more common in those with HIV/AIDS,28 heart disease,29 stroke,30 cancer,31 diabetes,32 Parkinson's disease,33 and many other illnesses. Research shows a person with both depression and a serious illness is more likely to experience severe symptoms and find it harder to adapt to the medical condition. Studies also show that treating depression in this population may improve symptoms of the co-occurring illness in some instances.

Additionally, people dependent on alcohol or narcotics are significantly more likely to be depressed.34

Mainstream Medicine Overlooks Factors that Contribute to Depression

The mainstream view on the cause of depression relies largely on the monoamine hypothesis—a theory proposing that deregulation in neurotransmitter signaling is the sole cause of depression. This has been the grounds for the primary utilization of antidepressant drugs in the management of depression for decades. However, this theory fails to take into account various other well-studied causes, and partly explains the poor success rate of antidepressant medications.

Conventional medicine overlooks several important biological factors that influence depression, thereby undermining the likelihood that a holistic strategy will be employed to thoroughly manage a patient’s depression.

If left unchecked, aberrations among these underappreciated factors may work together to create metabolic and neurochemical imbalances that provoke mood changes and initiate depression.

Critical omissions from conventional assessment of depression include:

  • Hormonal imbalances
  • Nutritional deficiencies
  • Oxidative stress and mitochondrial dysfunction
  • Insulin resistance and chronic inflammation

Hormonal imbalances. Balanced and youthful concentrations of hormones can help control depression, and astute clinicians often find hormonal imbalances in patients with depression. Because a wide range of hormones can influence depression, it is important to discern which hormone(s) may be an underlying factor when considering depression.

For example, thyroid function directly affects metabolism and brain function, and low thyroid activity can contribute to depression. Conventional medicine relies on overly broad thyroid lab ranges, failing to recognize many cases of sub-optimal thyroid function.

Overt hypothyroidism has been shown to perturb serotonin signaling in the brain, which can contribute to depression.35 Furthermore, because the brain requires sufficient thyroid hormones to function optimally, a low thyroid hormone status can contribute to overall loss of function and degeneration in the brain, including the areas of the brain that govern mood.36 Hashimoto’s thyroiditis, an autoimmune thyroid disease, can cause a person’s metabolism to swing between overly active to overly depressed. These swings can mimic the symptoms of bipolar disorder and cause misdiagnosis and inappropriate treatment.37-40

Sex hormones also influence mood and depression. Women are more susceptible to anxiety than men and also experience more depression when they are pregnant, postpartum, premenstrual and menopausal than at other times in life. These general observations have piqued the interest of scientists and given rise to an expanding body of research linking depression with sex hormone imbalances.

By now, it is well known that most steroid hormones (eg, pregnenolone, estrogen, progesterone, testosterone, and DHEA) are neurologically active. In fact, the brain contains large numbers of receptors for DHEA, estrogen, and progesterone. These hormones affect many functions in the brain, including the regulation of mood.

Accordingly, a number of studies link hormonal imbalances to various depressive disorders.41-44 In the follicular phase of menses, when estrogen levels are high, women produce more serotonin and experience an improved mood. When estrogen decreases during the premenstrual period, serotonin levels drop, contributing to the negative mood and personality shifts associated with PMS.45

Likewise, the drop in estrogen during menopause is associated with reduced serotonin production and a negative impact on mood and cognition. This is evidenced by the fact that SSRIs have been shown to improve mood and cognitive function in menopausal women.46

In addition, testosterone deficiency has been linked with depression in men, which is not surprising since testosterone plays an important role in brain function, including mood regulation.47,48 In studies, select populations of men were more likely to be depressed if their total and/or free testosterone levels are low; these included those with heart disease, HIV/AIDS, and the elderly.49,50

Medical research acknowledges the link between hormonal imbalances and depression; however, conventional doctors rarely evaluate and address hormone status when treating depression. Instead, they frequently dismiss such imbalances as a normal part of aging, while in truth, restoring youthful hormonal status may effectively combat multiple health deficits associated with aging, including mood imbalances.

The role of hormones in treating depression will be examined more closely in the section of this protocol entitled “Hormone Restoration.”

Nutritional deficiency or insufficiency. Nutrition plays an essential role in brain function, and poor nutrition significantly increases one’s risk for depression. Dietary nutrients influence nervous system function in multiple ways. Important dietary nutrients include:

  • B-complex vitamins. B-complex vitamins serve as cofactors for the production of neurotransmitters. Inadequate levels of B-vitamins, especially folate, vitamin B12, niacin, and vitamin B6, can disrupt neurotransmitter synthesis. This not only may lead to mood alterations, but also can impact overall brain function, memory, and cognition.
  • Optimal balance of omega-3 and omega-6 fatty acids. Fatty acids are critical components of nerve cell membranes and play an important role in neuronal communication. Fatty acid imbalances can impair the transmission of messages between nerve cells, leading to cognitive deficits and mood alterations, including depression.51
  • Vitamin D activity. A vitamin-D insufficiency, which is very common even among dedicated supplement users,52 is linked with seasonal depression. Recent evidence suggests that it also may contribute to general depression through its considerable influence on genetic activity, its ability to control inflammation, and other mechanisms.

It is important to remember that optimal brain function necessitates all of these nutritional aspects be addressed simultaneously.

Oxidative stress and mitochondrial dysfunction. Brain tissue is particularly susceptible to oxidative damage due to its high concentrations of phospholipids and the exhaustive metabolic rate among neurons. A growing body of research suggests that oxidative stress contributes to depression and other brain-related disorders.53 This is thought to result from either an increase in damaging reactive oxygen species, a decrease in antioxidant defense mechanisms, or a combination of the two. These mechanisms become especially important with advancing age.54

Newer research sheds light on the critical role of mitochondria and neurotransmission and mood regulation. Mitochondria are the “powerhouses” in each cell that generate energy. In an intriguing study, researchers measured the content of mitochondrial DNA within white blood cells in aging patients who were depressed, and in an age-matched group who were not depressed. The subjects with depression had significantly fewer mitochondria than non-depressed controls, leading researchers to suggest, “mitochondrial dysfunction could be a mechanism of geriatric depression.55 In a similar study, greater numbers of mitochondria in peripheral cells were associated with improved cognitive function in healthy elderly women.56

Preliminary research suggests that two nutrients, coenzyme Q10 and acetyl-L-carnitine, which support mitochondrial function, may influence depression. A small study of 35 depressed patients in comparison to 22 healthy volunteer controls showed that plasma CoQ10 levels were significantly lower in the depressed patients. Levels were also lower in treatment-resistant patients, as well as those with chronic fatigue.57

Several studies of geriatric depression have investigated acetyl-L-carnitine.58 One study compared treatment with acetyl-L-carnitine to the medication amisulpride, an antipsychotic medication commonly used to treat depression. In 204 patients with chronic depression, both acetyl-L-carnitine and the pharmaceutical drug improved symptoms.59 Acetyl-L-carnitine also has been found to relieve depression and improve quality of life in patients with liver disease,60 and to ease depressive symptoms significantly in patients with fibromyalgia.61

Another nutrient, pyrroloquinoline quinine (PQQ), is an enzyme involved in the generation of new mitochondria and the maintenance of antioxidant defense systems.62-64 Supplemental PQQ has been shown to increase mitochondrial activity levels and to be neuroprotective in animal models.65-67 Since fewer mitochondria have been observed in depressed patients,55 PQQ may be supportive in this population.

Insulin resistance. Recent data suggest a direct link between insulin resistance and depression. In a small clinical study, treatment of depressed patients with the insulin-sensitizing drug pioglitazone alleviated depression while simultaneously improving their cardio-metabolic risk profiles.68 Evidence suggests that another popular glucose control agent, metformin, may influence psychiatric health as well.69 Individuals who are overweight, have suboptimal glucose control, or have diabetes with concurrent depression may find that losing weight and gaining control over their glucose levels eases their depressive symptoms.

Scientific literature indicates that for optimal health, fasting glucose levels should fall between 70 and 85 mg/dL, and 2-hour postprandial (2 hours after a meal) glucose levels should not exceed 120 mg/dL.

Chronic inflammation. Several studies support the role of inflammation and immune system deregulation in depression. Studies have found elevated levels of inflammatory cytokines (signaling molecules with which immune cells communicate) in patients suffering from major depression,70 late-life depression,71 and in patients who do not respond to SSRIs.72 These cytokines include the interleukins IL-1beta and IL-6, as well as the cytokines INF-gamma and TNF-alpha.

Studies show an association between the systemic inflammation marker C-reactive protein (C-RP) and major depression.73 Moreover, elevated CRP levels are associated with a number of other significant health problems such as cardiovascular disease. Life Extension suggests that women target a CRP blood level of less than 1.0 mg/L and men target a level of less than 0.55 mg/L.

In prospective studies involving patients being treated with recombinant cytokines for immune-related conditions, depression is observed to develop after inflammation initiates several other undesirable metabolic cascades. This has led some researchers to identify depression as a late-stage consequence of chronic inflammation.74

Research innovations suggest that future antidepressant medications may be anti-inflammatory in nature.75

6 Conventional Medical Approaches – Challenges and Benefits

As mentioned earlier, mainstream medicine typically relies on antidepressants as first-line treatment for depression.4 However, in many cases, this first-line treatment is meant with failure. The result is a diagnosis of “treatment-resistant depression,” and, if severe enough, more drastic measures will be undertaken in attempt to alleviate depressive symptoms. Instead of addressing the multiple other potential contributors to depression mentioned in the protocol, conventional physicians opt to appease treatment-resistant depression with procedures like electroconvulsive therapy, which happens to cause memory loss.

Sadly, though research has given rise to promising new modalities for relieving depression, such as transcranial magnetic stimulation, mainstream medicine has yet to advance past the archaic model of psychiatric medicine that has been in place for decades.

This section of the protocol will discuss typical conventional treatment options and also introduce some promising new techniques that are quickly gaining the attention of patient-minded clinicians.

Medications Typically Used to Treat Depression

Several classes of medications may be employed to treat depression; depending on the patient’s symptoms and history medications from the following classes are typically utilized.

Most antidepressant medications work by altering signaling within the brain. They do so by manipulating the level of neurotransmitters in the synaptic junction, the finite space between two neurons in which signaling molecules are released and reabsorbed to facilitate neuronal communication.

While antidepressants may temporarily improve mood, they do so in a way that is somewhat artificial and unlikely to be effective for an extended time. There is disturbing evidence that some antidepressants may cause the brain to adapt to their presence, requiring increasing dosage and leading to withdrawal symptoms upon cessation.

Moreover, an underrecognized condition known as antidepressant discontinuation syndrome may arise in as many as 20% of patients upon abrupt discontinuation of an antidepressant medication. This phenomenon is likely the result of the brain having adapted to the medication, and now being deprived of it, malfunctions for a time until it can readapt to the lack of the drug. Symptoms of antidepressant discontinuation syndrome include flu-like symptoms, insomnia, nausea, hyperactivity, and sensory disturbances, among others.76

1. Selective serotonin reuptake inhibitors (SSRIs) are one of the most popular class of antidepressants. Fluoxetine (Prozac), citalopram (Celexa), and sertraline (Zoloft) are all SSRIs. They tend to have the fewest side effects of antidepressant drugs. Primary side effects are decreased sexual desire and delayed orgasm. Other side effects—digestive symptoms, headaches, insomnia and anxiousness—often decrease over time.77

2.Serotonin and norepinephrine reuptake inhibitors (SNRIs) include duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq). The side effects for these medications are similar to those of SSRIs.

3. Atypical antidepressants are norepinephrine and dopamine reuptake inhibitors (NDRIs) such as bupropion (Wellbutrin), trazadone (Desyrel), and mirtazapine (Remeron). They have a different mechanism of action and side-effect profile than other antidepressants. For example, NDRIs generally do not cause sexual dysfunction as a side effect; however, they can increase blood pressure and risk of a seizure. Other minor effects include loss of appetite, headaches, dry mouth, nervousness, anxiety, stomach pain, constipation, insomnia, and more.

4. Older antidepressants include the tricyclic antidepressants amitriptyline, amoxapine, desipramine (Norpramin), doxepin, imipramine (Tofranil), nortriptyline (Pamelor), protptyline (Vivactil), trimiptyline (Surmontil); and the monoamine oxidase inhibitors (MAOIs) tranylcypromine (Parnate) and phenelzine (Nardil). Doctors do not use these medications frequently because they tend to have more frequent and severe side effects. For example, tricyclic antidepressants can cause an abnormal heart rhythm and drowsiness. MAOIs can increase the risk of severe reactions to foods, drinks and other medications, as well as significantly increase blood pressure, which may lead to a heart attack or stroke. Other side effects of both these classes of medication include constipation, headaches, anxiety, and dry mouth.

Electroconvulsive Therapy

A long-standing treatment still used in conventional medicine is electroconvulsive therapy, or ECT. It is most often reserved for people with suicidal ideation, psychotic depression, or those who have not responded to other treatments. It is reportedly effective in up to 90% of patients, which is why it is still available,78 although it is important to question the extent of the benefit and how long the effects last.

ECT is associated with short-term memory loss, and it appears that some aspects of memory may be affected for an extended time.79 Moreover, ECT may negatively influence other realms of cognition unrelated to memory; in fact, one group of reviewers stated that “…clinicians should take the non-memory cognitive effects of ECT into account, and patients should be informed of their existence before they sign consent for ECT.80

7 Other Medical Approaches and Emerging Therapies

Cognitive Behavioral Therapy

Cognitive behavioral therapy (CBT) is a non-pharmacologic means of therapy often employed to relieve depression. CBT is typically initiated if primary treatment with antidepressant medications fail, but it is sometimes used as part of first-line treatment alongside antidepressants.

CBT is centered upon the belief that depression is closely linked with negative thinking (ie, thought patterns that negatively reinforce depressed mood). The goal of CBT is to help the patient recognize and replace negative thinking with more positive, constructive thoughts. CBT has been studied in various settings and has shown efficacy both independently and in combination with other conventional treatment regimens.

A recent review of studies using CBT in treatment-resistant depression found that CBT performed as well as pharmacotherapy when used in conjunction with a primary medication, or in cyclical fashion involving switching from pharmacotherapy to CBT and back again.81 This same review also pointed out that when a patient with treatment-resistant depression switched antidepressants, greater relief was attained when the switch was accompanied by CBT. A 2010 clinical trial revealed that CBT effectively relieved depression and/or anxiety in patients with chronic obstructive pulmonary disease.82

CBT is also effective in young people with depression, and may be preferable over psychotropic drugs for some parents since it lacks harsh side effects. In one trial, CBT was compared to stand-of-care (pharmacotherapy) in children ages 8–15. CBT was superior to pharmacotherapy in several aspects, including patient alliance to treatment. Moreover, CBT may have an overall cost advantage versus pharmacotherapy.83

Life Extension suggests that every patient with depression talk with a qualified healthcare provider about cognitive behavioral therapy as an adjuvant, or alternative to pharmacotherapy.

Physical Activity

Research supports the use of exercise, primarily aerobic or weight training, as a preventive and adjuvant treatment (used in conjunction with medication) of mood disorders and depression. Some studies have found exercise alone is as effective as medication for relieving depression84 and that exercise can reduce depression recurrence rates.85 A recent study looked at 202 adults with major depression who either participated in four months of exercise, took the medication sertraline, or took a placebo. A one-year follow up showed that exercise was as effective as the medication at relieving depression and that exercise during the follow-up period extended the benefits.86

Light Therapy

Research shows morning light therapy from a light-therapy lamp is effective at treating seasonal affective disorder (seasonal depression), and that it is equally or possibly even more effective than antidepressants, in this type of depression.84 A study of 98 patients with seasonal depression illustrated this. Depressed subjects were randomly assigned to eight weeks of therapy with light in the morning (30 minutes, 10,000 lux, and a placebo pill) or 30 minutes of dim light (100 lux and 20 mg of fluoxetine), with both groups experiencing a 67% response rate.87

Light therapy for non-seasonal depression is not well established, although results are promising; light therapy may be more helpful as an adjuvant treatment than as a stand-alone treatment.

Transcranial Magnetic Stimulation

Interestingly, a new procedure called transcranial magnetic stimulation (TMS), which uses magnetic fields to stimulate nerve cells in the brain, is widely researched and showing promising results as a treatment for depression. The FDA has approved TMS for people who have not responded to medication, and it is often compared to the controversial electroconvulsive therapy (ECT). However, it is a possible alternative to ECT, as it is more humane and causes fewer adverse effects.

A recent study of 190 patients with major depression treated with TMS showed a clinically significant improvement in symptoms.88 In a recent review, TMS was concluded to be as effective as cognitive behavioral therapy or pharmacotherapy for relieving depression.89

TMS is becoming more widely available in hospitals and private practices; however, because it is relatively new, it is important to ask how long the treatment has been offered, how many patients have been treated, and what the success rates are.

Dietary Considerations for Depression

Dietary factors should always be addressed when managing depression, as evidence demonstrates that various aspects of diet can affect the disorder.

Individuals with depression may consume too many inflammatory omega-6 fatty acids and saturated fats, so increasing consumption of omega-3's and decreasing consumption of trans-fats, saturated fat, and excess omega-6 fatty acids is recommended.90

Omega-3 fatty acids91 and folate92 both appear to be very important in mood management. Although the role of these nutrients in the diet is important, one should augment the diet with supplements for maximum benefit in addressing symptoms of depression or in trying to prevent a recurrence. As described later in this protocol, omega-3 fatty acids have been shown to decrease susceptibility to depression and may help as an adjuvant therapy. Foods high in omega-3's include deep-water fish such as salmon, mackerel, sardines, and tuna, as well as flax seeds, and some nuts (eg, walnuts).

Evidence suggests that limiting sugar intake to control blood sugar levels is another important approach to depression. This would include addressing hyperglycemia (high blood sugar), hypoglycemia (low blood sugar), or reactive hypoglycemia (low blood sugar that occurs within 4 hours of eating). Reactive hypoglycemia may be more common in people who are not overweight. To address high or low blood sugar, it is important to limit or avoid sugar and refined carbohydrates, eat small meals 4–6 times per day, eat a balance of healthy proteins, fats, and complex carbohydrates, and decrease caffeine. The nutrients magnesium and chromium and practicing relaxation techniques also help manage hypoglycemia.

Evidence also suggests that an anti-inflammatory Mediterranean Diet may help prevent or manage depression.93 A Mediterranean diet, which is rich in omega-3 fatty acids and polyphenolic antioxidants, could serve as a foundation to which targeted dietary supplements are added for maximum response. The diet generally includes good quantities of fish, vegetables, unrefined grains, beans or legumes, fruit, and olive oil. It includes moderate amounts of dairy (mostly cheese and yogurt) and red wine, and limits meats to small portions.

8 Complementary Therapies for Depression

Hormone Restoration Therapy

Although some physicians routinely screen for underlying hormonal disorders and/or imbalances as part of depression management, many use hormonal therapy in protocols for depression, most typically do not. Instead, they may consider hormonal imbalances a normal part of aging. Also, many ascribe to the philosophy of looking at studies of averages of population data as opposed to individual cases for potentially beneficial therapeutic programs, which can cause patients who may benefit from hormone restoration to go untreated.

Thyroid. Thyroid dysfunction may be a significantly underappreciated cause of depressive symptoms. In one study, thyroid disorders were associated with a 22% higher likelihood of depression in women.94

Studies have shown that treating subjects within so-called “normal” thyroid hormone levels may still be beneficial. In one such pilot study involving 17 female patients with depression, 11 (64.7%) saw significant improvement in response to a moderate dose of l-thyroxine.95 Similarly, in a study of 225 subjects with treatment-resistant depression, augmenting primary antidepressant therapy with thyroid hormone was found to be roughly as effective as adding a second antidepressant medication for providing relief of symptoms.96

Life Extension suggests maintaining a TSH (thyroid stimulating hormone) of 1–2 µIU/mL (typical lab normal range 0.45‒4.5 µIU/mL) to avoid the consequences of subclinical thyroid dysfunction, which may include depression. To learn more about sub-optimal thyroid function and how it may be impacting your life read our Hyperthyroidism and Hypothyroidism protocols.

DHEA. DHEA is an important steroid hormone often referred to as a neurosteroid because it serves a variety of functions in the brain. DHEA levels decrease with age and stress, and people with depression often have low levels of DHEA. In one study, blood samples from women with a history of depression contained lower levels of select neurosteroids, including DHEA, than women with no depression history.97 Interestingly, experiments showed the women with a history of depression may metabolize progesterone differently than healthy women, reflecting an adaptive effort by the body to compensate for low neurosteroid levels.

A number of studies have examined the role of DHEA in depression, with very encouraging results. DHEA has been shown to modulate serotonin levels in the brains of laboratory animals.98,99 DHEA has also performed well in human trials. DHEA therapy significantly benefited patients with HIV/AIDS and depression.100 In a randomized, placebo-controlled, double-blind study, researchers studied the effects of 90 mg DHEA daily for three weeks and 450 mg daily for three weeks as a stand-alone treatment for both mild and severe depression. They found that DHEA therapy resulted in a significant improvement in symptoms compared with the placebo.101

Testosterone. Studies indicate that some depressed men have low levels of testosterone.102,103 In addition, several clinical trials have shown that testosterone replacement therapy, usually transdermal testosterone gel, can relieve depression in men with low testosterone, metabolic syndrome, and HIV/AIDS.50,104-106

Aging men should maintain their free testosterone level in the youthful range of 20–25 pg/mL to stabilize mood and avert other age-related diseases, such as cardiovascular disease and metabolic syndrome. Men interested in restoring their hormone levels should read Life Extension's “Male Hormone Restoration” protocol.

Estrogen. Estrogen is critically important for brain function and linked to depression, especially in perimenopausal or postmenopausal women.107 Women using estrogen replacement therapy to alleviate menopause symptoms appear to experience reduced depression.108 In some older women being treated for depression, estrogen replacement therapy may actually improve the effects of conventional antidepressants.109

Estrogen is thought to prevent depression through its association with serotonin regulation in the brain.110-112 Animal studies show that estrogen may facilitate the effects of antidepressants by modulating serotonin receptors. This suggests that an estrogen imbalance may dampen the efficacy of antidepressant medications.113,114

Further evidence suggests that estrogen promotes neuroplasticity, the process by which the brain adapts structurally and functionally to new stimuli.110,115 Disturbances in neuroplasticity may lead to recurrent depression.116

Women interested in learning more about the benefits of restoring their hormone levels should read Life Extension's “Female Hormone Restoration” protocol.

Melatonin. Melatonin is a hormone produced in the pineal gland in the brain; it is involved in sleep-wake function and other circadian rhythms. Melatonin decreases with age and some studies link low levels of melatonin with symptoms of depression.

A double-blind placebo-controlled pilot study of perimenopausal and post-menopausal women who took 3 mg of melatonin at bedtime for six months showed significant improvement in depressive symptoms.117 Recently, another well-controlled preliminary study looked at 33 participants with major depression and early morning waking who took 6 mg of melatonin for four weeks. The results suggested improvement in sleep and depressive symptoms.118

Studies of the medication agomelatine, which acts upon melatonin receptors in the brain, support melatonin's influences on depression.119 Some studies suggest that this drug may be as effective as venlafaxine, fluoxetine, and sertraline in relieving depression.120

9 Nutrients to Balance Brain Chemistry

Depression is a multifactorial condition, and efficient relief often requires addressing multiple neurochemical and metabolic imbalances that may underlie mood disturbances.

Many of the nutrients in this section may serve as adjuvants to conventional therapies for depression. Always consult a qualified healthcare professional before combining any supplements with an antidepressant medication.

The nutrients listed in this section are categorized according to their evidence-based mechanisms of action in brain health and mood regulation. The categories are:

Broad-Range Nervous System Effects

Omega-3 fatty acids. Omega-3 fatty acids are long-chain polyunsaturated fatty acids found in fish and various oils, such as flaxseed or canola oil.121 The brain has a high concentration of polyunsaturated fatty acids, which are found mostly in cell membranes. They affect adaptability of the nervous system, nerve cell conduction and function, and neurotransmitter synthesis.51,122 Several research models exhibit the influence of omega-3 fatty acids in depression including: (a) dietary studies123; (b) nutritional status studies showing positive effects associated with higher omega-3 to omega-6 fatty acid ratios124; and (c) intervention studies that look at both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) taken as a stand-alone treatment and as an adjunct to medication.91

One investigation showed that adding the omega-3 fatty acid EPA to conventional antidepressant treatment relieved depressive symptoms.125 Among children with depression, supplementation with omega-3 fatty acids demonstrated “highly significant” effects on symptom scores.126 In a review article from 2006, researchers analyzed results from six published studies and found that omega-3 fatty acids can reduce symptoms of depression among adults as well.127

Because they are anti-inflammatory, omega-3 fatty acids also reduce the risk of cardiovascular disease, which is highly associated with depression.128,129 In fact, the American Heart Association recommends fish oil for both preventing an initial heart attack and for preventing a second attack when one has already occurred.

Omega-3 fatty acids are counterbalanced with the inflammatory omega-6 fatty acids. Typically, Americans consume far too many omega-6's and not nearly enough omega-3's.

The ratio of omega-6 to omega-3 fatty acids is important. You can learn your ratio easily with the Omega-3 Index test. This test can help you assess your risk for depression, heart disease, and other age-related ailments. It can also help you evaluate whether you take enough fish oil or other omega-3 supplements. More information about the importance of maintaining an optimal omega-6 to omega-3 ratio of less than 4:1 can be found in the Life Extension Magazine article entitled “Optimize your Omega-3 Status.”

Magnesium. Magnesium is a cofactor for more than 300 enzymes in the body; it is important for blood-sugar regulation, and has a calming effect on the nervous system.130 Some evidence shows a link between magnesium deficiency and depression,131 and a recent, comprehensive review in the Journal of Medical Hypotheses suggests that magnesium supplementation is a viable approach for depressive symptoms.132

A major hurdle for supplemental magnesium historically has been delivery into the brain. This is a barrier that has limited the ability of typical magnesium supplements to target conditions that arise from within the central nervous system such as depression and anxiety. However, in a recent scientific breakthrough, researchers collaborating from Beijing, Ontario, the University of Texas, and the Massachusetts Institute of Technology have developed a highly advanced form of supplemental magnesium called magnesium-L-threonate.

Magnesium-L-threonate was shown in multiple animal models to not only effectively penetrate deep into the brain, but also to trigger enhancements in learning and memory by optimizing neuronal communication and reinforcing brain structure in key areas of the cortex, the most advanced aspect of the human brain.133,134 Since magnesium-L-threonate is readily able to diffuse across the blood brain barrier, while other forms of magnesium are not, it appears to be the ideal form of supplemental magnesium for those with depression of other mood disorders.

Saffron extract. Saffron and its constituents have multiple biochemical activities that help provide supporting evidence for saffron in the treatment of depression. These include serotonin modulation as well as neuroprotective, neuro-hormonal, anti-inflammatory, and oxidative stress reducing functions.135-137 In an advanced laboratory study, two saffron compounds, crocin and safranal, inhibited the activity of enzymes that lower levels of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine in brain synapses.138

Two randomized controlled trials found 30 mg per day of saffron extract to be as effective for mild-to-moderate depression as 20–40 mg per day of the antidepressant drug fluoxetine.139,140 In another randomized placebo-controlled trial, 40 patients hospitalized with major depressive disorder were given 15 mg of the saffron extract crocin, twice daily, in addition to antidepressant medication. Patients taking crocin had significantly greater improvement in anxiety and depression scores than those who received placebo plus antidepressant.141

In a controlled clinical trial, 60 individuals with depression and anxiety were treated with either 50 mg saffron twice daily or placebo for 12 weeks. The saffron group had significantly reduced depression and anxiety symptom scores on standardized questionnaires compared with placebo.142 In another controlled clinical trial in 40 patients with mild-to-moderate depression, six weeks of treatment with 15 mg saffron extract, twice daily, resulted in a more than 2.7-fold greater reduction in standardized depression symptom scores compared with placebo.143 A similar study also found treatment for six weeks with 30 mg per day saffron extract was significantly more effective than placebo at improving depression symptoms scores in individuals with mild-to-moderate depression.144

One relatively common side effect of SSRIs is sexual dysfunction in both men and women.145 Two controlled clinical trials, one in men and one in women, found saffron safely and effectively relieved some symptoms of antidepressant-induced sexual dysfunction.146,147 One study in women with premenstrual syndrome, a condition often treated with antidepressants, found saffron was significantly more effective than placebo for relieving symptoms, including depression, of this condition.148 In this randomized controlled trial, 50 women received either 15 mg saffron extract or placebo twice daily for two consecutive menstrual cycles. Sixty percent of the saffron group had a 50% or greater reduction in depression symptoms versus 4% in the placebo group. Seventy-six percent of the saffron group experienced a 50% or greater reduction in PMS symptoms versus 8% in the placebo group.149

Supporting Neurotransmitter Synthesis

Tryptophan. L-tryptophan is essential for the brain to synthesize serotonin, and several studies have shown that acute tryptophan depletion can cause depression in humans. In fact, some foreign countries license L-tryptophan as an antidepressant.150

In one study, healthy women given L-tryptophan for 14 days experienced increased recognition of happy faces and words, and decreased recognition of negative words. The research team concluded L-tryptophan had improved the study participants' supply of serotonin in a manner similar to that of SSRIs.150 In another study of the effects of acute tryptophan depletion on healthy women and on patients with bulimia nervosa, both groups were given amino acid mixtures to decrease their plasma L-tryptophan levels. Both groups experienced an increase in depression.151 Other studies have found L-tryptophan depletion can lead to recurrence of depression in those who are in remission from depression152 or in those with seasonal depression.153

Methylation is a process in which a molecule passes a methyl group to another molecule. Methylation is essential to multiple functions in the body, including the production of neurotransmitters. One can supply raw materials to support methylation reactions by supplementing with S-adenosyl-methionine (SAMe) or by providing metabolic cofactors such as folate, vitamin B12, and vitamin B6. These nutrients are necessary for neurotransmitter production and have other regulating effects.

S-adenosylmethionine (SAMe). SAMe, which can be found in almost every tissue in the body, assists with production of creatine, glutathione, taurine, L-carnitine, and melatonin.

Research shows SAMe can benefit depressed patients who do not respond to SSRIs. In a well-controlled, 6-week, double-blind trial, 73 subjects with treatment-resistant depression were treated with an SSRI plus placebo, or an SSRI plus 1,600 mg SAMe daily. The group receiving the SAMe experienced significantly better response rates and remission compared to the placebo control group.154 Intriguingly, the group that received SAMe also displayed improved memory function over those receiving placebo. A smaller 6-week study revealed a response rate of 50% and a remission rate of 43% in subjects taking 800–1,600 mg a day of SAMe as an adjunct to their antidepressants.155

Folate. Research shows that low blood levels of folate are associated with depression,156 and may also be predictive of poor response to antidepressant medication.157 Clinical trials have also demonstrated that folic acid both relieves depression on its own and enhances the effect of antidepressants. In one study, patients given 500 mcg folic acid daily in conjunction with fluoxetine experienced a significant improvement in depressive symptoms compared with patients receiving the antidepressant alone; women particularly benefited.158 Because relapse is associated with low serum folate, it is important to maintain folate supplementation for a year following a depressive episode.159

The form of supplemental folate is important since a considerable portion of Americans may have a genetic polymorphism that impairs folate metabolism.160 In fact, mutations in the gene (MTHFR) that converts folic acid into the active 5-methyltetrahydrofolate (5-MTHF) are associated with depression.161 Therefore, taking supplemental 5-MTHF directly, which can cross the blood-brain barrier, may be more effective in supporting healthy neurotransmission and decreasing potentially neurotoxic homocysteine levels.

Vitamin B12. Vitamin B12 should always be measured in the event of depression (or any other psychological problems) as a vitamin B12 deficiency can be a reversible cause of various neuropsychiatric disorders.162 One should also consider whether a vegetarian diet or malabsorption due to celiac disease or gluten enteropathy is a factor in B12 deficiency.

Weaker digestion, reduced absorption of nutrients, and hypochlorhydria (inadequate stomach acid needed to break down proteins that contain vitamin B12) are common in the aging population and associated with a B12 deficiency; B12 levels should be tested in an older person with symptoms of depression. Evidence suggests that the methylcobalamin form of B12 may have more beneficial metabolic effects than cyanocobalamin.163,164

Vitamin B6. Vitamin B6 is a cofactor for the production of most neurotransmitters, but it is particularly important for serotonin synthesis.165 B6 levels are often low in women taking oral contraceptives and research has shown that B6 supplementation in these women can improve mood. For example, one study showed 22 women who had depression associated with oral contraceptive use and a B6 deficiency saw significant improvement in their symptoms with B6 supplementation.166

A more recent study examined blood levels of pyridoxal-5-phosphate (P5P), a metabolically active form of B6, in the blood of 251 elderly individuals living is Massachusetts. The investigators found that deficient levels of P5P doubled the likelihood of depression in this population. Accordingly, when dietary composition was assessed, those with higher daily B6 intakes were less likely to be depressed.167

Blood Sugar Regulation and Insulin Resistance

Green coffee. Recent data link increasing consumption of coffee with decreased risk of depression.168 In fact, this relationship proved to be dose-dependent, meaning that the more coffee study participants drank, the less likely depression would strike them. These findings are corroborated by a similar study conducted in 2010, which supports the link between increasing coffee consumption and decreased depression risk.169 Interestingly, this last trial was unable to link caffeine with depression risk, suggesting that other compounds in coffee may be responsible for the mood-elevating effect.

Conventional coffee preparation, which involves roasting the green coffee beans at high temperatures to attain the desired flavor profile, dramatically lowers levels of health-promoting coffee constituents called chlorogenic acids.

Chlorogenic acids have been shown in several studies to aid in controlling blood sugar levels; especially those glucose spikes which occur after a high-carbohydrate meal.170,171 In a 12-week study, consumption of chlorogenic acid-fortified instant coffee led to a considerable reduction in the absorption of glucose when compared to regular instant coffee.172 As elevated glucose levels are common among depressives, chlorogenic acids may help combat some symptoms of depression tied to insulin resistance and irregularities in glucose metabolism.

Green coffee, the primary source of chlorogenic acids, cannot be consumed as a beverage due to its extremely bitter taste. Consuming a green coffee extract standardized to chlorogenic acids is an effective means of obtaining biologically active concentrations of chlorogenic acids.

The potential role of chlorogenic acids in mediating the mood boost associated with coffee consumption, and their thoroughly studied antihyperglycemic properties give rise to promising multimodal depression protection.

Chromium. Chromium has been studied for its role in regulating blood sugar by facilitating the uptake of glucose into cells, and some research indicates that it may be beneficial in depression as well.173

In one case series of five patients with minor depression, chromium supplementation led to remission.174 Two other pilot studies found chromium picolinate supplementation benefited atypical depression.175,176 Finally, although not studied for seasonal depression, chromium may help regulate blood sugar and cravings for sugar and carbohydrates in relation to seasonal depression.

Antioxidant Effects

N-acetyl cysteine (NAC). One of the best-researched antioxidants for depression is N-acetyl cysteine (NAC). NAC is a precursor to glutathione, one of the body's most powerful antioxidants. Research has found glutathione depletion and oxidative stress in people with bipolar depression. Two recent studies showed NAC is a safe and effective adjunctive treatment that improves depression in patients with bipolar disorder.177

Lipoic acid. Although lipoic acid has not been well studied for depression, it is one of the most effective supplemental antioxidants, since it helps recycle other antioxidants, such as vitamin C. It also may benefit blood sugar regulation and neurological function, as evidence shows it can help diabetic neuropathy.178

Vitamins C, E, and selenium. In general, antioxidants may help buffer nerve cell damage in cases of chronic or recurrent depression, although they also serve other roles in brain health. For example, the antioxidant vitamin C is an important cofactor in the synthesis of serotonin, norepinephrine, and adrenal hormones that mediate stress. Vitamin E helps protect nerve cell membranes, and low selenium levels are associated with depression.179

Additional Nutrients

Curcumin. Curcumin is a phytoceutical derived from turmeric, a spice used often in preparation of Indian cuisine. It belongs to a class of compounds called polyphenols, which have been extensively studied and shown to exert an array of health benefits. One of the most intriguing properties of polyphenols, and curcumin in particular, is the ability to positively influence mood.180 Indeed, mounting evidence suggests curcumin might represent an important novel modality for the treatment of depression.181

Curcumin appears to modulate several aspects of neurobiology involved in mood and behavior. Experimental evidence from an animal model of depression suggests curcumin can preserve levels of a protein important for healthy neuronal function (brain-derived neurotrophic factor [BDNF]) in a region of the brain called the amygdala, which is involved in mood regulation.182 Curcumin appears to manipulate neurotransmitter signaling as well. In another animal model, mice with neuropathy (who are prone to depression) were treated for three weeks with 45 mg/kg of curcumin twice daily (about 583 mg daily for an 80 kg adult human). While these mice normally exhibit depressive-like symptoms, curcumin treatment ameliorated this behavior. Interestingly, the researchers found that curcumin may have eased the rodent’s depression by altering serotonin and gamma-aminobutyric acid (GABA) signaling in their central nervous systems.183 Curcumin also helps relieve pain, which may be helpful for some individuals with depression because pain, especially of chronic nature, is closely—and potentially causally—associated with depression.183-186 Other studies show that curcumin’s powerful anti-inflammatory properties may also underlie its ability to elevate mood. In an experiment in which rats were exposed to chronic stress for 21 days to induce depressive-like behavior, curcumin administration was shown to significantly reduce signs of depression. This study also showed that curcumin considerably eased inflammation by suppressing activation of nuclear factor-kappaB (NF-κB), a master regulator of inflammation; the researchers concluded that curcumin’s antidepressant effects were due in part to its anti-inflammatory action.187

Evidence for a potent antidepressant effect of curcumin among animals has been partially confirmed in at least one human study. In a randomized, double-blind, placebo-controlled trial, 40 people with new-onset depression were treated with antidepressants (escitalopram [Lexapro] or venlafaxine [Effexor]) together with either curcumin (500 mg per day) or placebo for five weeks. Researchers then tracked subjects’ depression severity using several standardized assessments. Although subjects in both groups experienced comparable relief of their depression, those who received curcumin tended to achieve faster relief than those who received a placebo.188

A plethora of animal data indicate curcumin may be a powerful tool in the treatment of depression, and, as of the time of this writing, additional human studies are ongoing to assess its effects on mood (SHSC 2014). Lastly—and perhaps most importantly—curcumin, unlike conventional antidepressant medications, has an excellent safety and side-effect profile.189-193

St. John's wort. St. John's wort (Hypericum perforatum) is a medicinal herb used to treat neurological and psychiatric disorders, including depression.194 Compared to a placebo, H. perforatum extract is more effective at targeting mild to moderate depression, and reducing symptoms and recurrence rate.195 Its effectiveness is considered comparable to antidepressant medications, but its actions are more complex.196,197

St. John's wort's mechanism of action on depression is not entirely understood, even though it is one of the most researched herbs for depression. St. John's wort has been shown to inhibit serotonin and norepinephrine reuptake, thus increasing their availability at the synapse.194 Other investigators found it influences dopamine and GABA activity. Its antidepressant qualities also can be linked to its antioxidant and anti-inflammatory properties that normalize an overactive hypothalamus-pituitary-adrenal axis and stress response.198

While additional research is ongoing to identify all of the antidepressant mechanisms of action, experimental models and clinical trials alike have shown that treatment with St. John's wort delivers positive response rates for mild-to-moderate depression.199-201

Unfortunately, potential side effects associated with St. John's wort deprive many depressives of its benefits.

Vitamin D. Growing evidence suggests that vitamin D significantly affects depression. This is not surprising in seasonal depression, since the skin synthesizes vitamin D in response to sunlight, which is less available in the winter.202,203 However, vitamin D has been found to play other roles in depression. For example, in a study of 7,358 patients age 50 and over with a cardiovascular diagnosis and no history of depression, low vitamin D levels significantly increased the risk of developing depression.204

Studies also find that vitamin D3 (cholecalciferol) supplementation can improve symptoms of depression. One well-controlled study of 441 overweight and obese participants showed an association between low vitamin D levels and depression. High dose vitamin D supplementation (20,000–40,000 IUs per week or 2,800–6,000 IUs per day) for one year improved mood.205 Another pilot study noted significant improvement in depression in six of nine women with low levels of vitamin D upon supplementation.203

Vitamin D's effectiveness may be related to the high prevalence of vitamin-D deficiency in the general population, its importance in blood-sugar regulation, and its importance in overall regulation of genetic activity.

Zinc. Zinc is a trace element known to help regulate the nervous system206 and may be specifically related to depression.207 Increasing evidence shows that decreased blood levels of zinc are associated with depression,208-210 and, in depressed subjects, lower levels of zinc are associated with worse depression.211 One pilot study of 20 depressed patients also showed that 25 mg a day of zinc augmented benefits of antidepressant medication.212

Animal studies show that antidepressants and electroconvulsive shock treatments change zinc concentrations in areas of the brain associated with depression.211 In further animal research, zinc also was shown to enhance antidepressant effects of imipramine213 and influence serotonin levels and activity in several brain regions.214

Inositol. Inositol levels in the brain and cerebrospinal fluid were found to be lower in subjects with depression. One well-controlled trial showed that taking 12 grams a day of inositol helped relieve symptoms in 39 patients with depression.215

Further research on bipolar depression suggests beneficial influences of inositol.216 A well-controlled but small trial of 17 participants with bipolar depression showed varied responses. Four of nine patients experienced significant improvement with inositol supplementation compared to zero of eight who took a placebo.217

Inositol, a second-messenger precursor, has important cellular communication functions in the nervous system. Interestingly, inositol is also involved with insulin signaling and function. It therefore may have more of an effect on overweight or obese individuals, as well as those who are insulin resistant, such as those with metabolic syndrome or women with polycystic ovarian syndrome (PCOS). These findings require further research and replication.

Probiotics. Emerging research has revealed an important relationship between the gastrointestinal tract and its billions of resident organisms—often referred to as the microbiome—and the brain. This has been termed the “gut-microbiota-brain axis.”218-223 Probiotics are organisms which, when consumed in adequate doses, exert a beneficial effect on health.224 Probiotics, which are able to modulate the gut-brain axis, have been shown in preclinical and clinical trials to ameliorate behaviors and symptoms of stress, anxiety, and depression.225-227

Lactobacillus helveticus (L. helveticus) R0052 has been researched, in combination with another proprietary probiotic strain, Bifidobacterium longum (B. longum) R0175, as a probiotic for psychological health.227-229 Rats given a daily dose of a combination of L. helveticus R0052 and B. longum R0175 for two weeks had markedly reduced signs of anxiety compared to those treated with a placebo. In fact, the probiotics reduced anxious behaviors to a similar degree as diazepam (Valium), the prescription anti-anxiety medication.227,230

In a double-blind randomized clinical trial, 55 healthy volunteers took a supplement containing three billion colony-forming units (CFUs) of the combination of L. helveticus R0052 and B. longum R0175, or placebo, for 30 days. The probiotic treated group had significantly lower scores on anxiety, anger, and depression symptom scales, with particular improvement in symptoms of depression.227 Among a subset of 25 participants considered to have low levels of chronic stress based on low urinary cortisol levels, the combination of L. helveticus R0052 and B. longum R0175 appeared to act as a preventive, suggesting it may be able to protect against stress-related diseases.229

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.

  1. CDC. Centers for Disease Control and Prevention. Current Depression among Adults – united states, 2006 and 2008 Morbidity and Mortality weekly Report October 1, 2010 Erratum. Availble at: Accessed 10/31/2011.
  2. Andrews G et al. Lifetime risk of depression: restricted to a minority or waiting for most? Br J Psychiatry. 2005 Dec;187:495-6.
  3. Howland RH. Use of endocrine hormones for treating depression. J Psychosoc Nurs Ment Health Serv. 2010 Dec;48(12):13-6. doi: 10.3928/02793695-20101105-01. Epub 2010 Nov 22.
  4. ICSI. Institute for Clinical Systems Improvement. Health care Guideline: Major Depression in Adults in Primary Care. May 2011. Available at Accessed 11/2/2011.
  5. Prescrire Int. Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice. Prescrire Int. 2011 May;20(116):128-33.
  6. Parker G et al. 'D' for depression: any role for vitamin D? 'Food for Thought' II. Acta Psychiatr Scand. 2011 Oct;124(4):243-9. doi: 10.1111/j.1600-0447.2011.01705.x. Epub 2011 Apr 12.
  7. Liu RT, Alloy LB. Stress generation in depression: a systematic review of the empirical literature and recommendations for future study. Clin Psychol Rev 2010a;30:582-93.
  8. Maes M et al. Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Sep 16. [Epub ahead of print]
  9. Wolkowitz OM, Reus VI, Mellon SH. Of sound mind and body: depression, disease, and accelerated aging. Dialogues Clin Neurosci 2011b;13:25-39.
  10. Joëls M. Impact of glucocorticoids on brain function: relevance for mood disorders. Psychoneuroendocrinology. 2011 Apr;36(3):406-14.
  11. van Riel E, Meijer OC, Steenbergen PJ, et al. Chronic unpredictable stress causes attenuation of serotonin responses in cornu ammonis 1 pyramidal neurons. Neuroscience. 2003;120(3):649-58.
  12. Karten YJ, Nair SM, van Essen L, et al. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. Proc Natl Acad Sci USA. 1999 Nov;96(23):13456-61.
  13. Anacker C, Zunszain PA, Carvalho LA, et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology. 2011 Apr;36(3):415-25.
  14. Ströhle A, Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S207-14.
  15. Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry. 2010 Jun;15(6):574-88.
  16. Bennett AO MR. Stress and anxiety in schizophrenia and depression: glucocorticoids, corticotrophin-releasing hormone and synapse regression. Aust N Z J Psychiatry. 2008; 42(12):995-1002.
  17. McCown D, Reibel DK, Micozzi MS. Teaching mindfulness: a practical guide for clinicians and educators. Springer Science and Business Media, LLC, New York, 2010.
  18. Newberg AB. The neurobiology of meditation. In Monti DA, Beitman BD (eds), Integrative Psychiatry. Oxford, England: Oxford University Press, Inc., pp. 339-58, 2010.
  19. Katsamanis MK, Lehrer PM, et al. Preliminary results of an open label study of heart rate variability biofeedback for major depression. Appl Psychophys Biofeedback 2007;32:19-30.
  20. Dusek JA, Otu HH, Wohlhueter AL, et al. Genomic counter-stress changes induced by the relaxation response. PLoS One. 2008 Jul;3(7):e2576.
  21. Dusek JA et al. Mind-body medicine: a model of the comparative clinical impact of the acute stress and relaxation responses. Minn Med. 2009 May;92(5):47-50.
  22. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64 Suppl 18:25–30.
  23. Grav S et al. Association between social support and depression in the general population: the HUNT study, a cross-sectional survey. J Clin Nurs. 2011 Oct 24. doi: 10.1111/j.1365-2702.2011.03868.x. [Epub ahead of print]
  24. Kiecolt-Glaser JK, Gouin JP, et al. Close relationships, inflammation and health. Neurosci Biobehav Rev 2010;35:33-8.
  25. Coughlin PA. Facilitating emotional health and well-being. In Monti DA, Beitman BD (eds), Integrative Psychiatry. Oxford, England: Oxford University Press, Inc., pp. 383-407, 2010.
  26. Yang YK, Yeh TL, Yao WJ et al. Greater availability of dopamine transporters in patients with major depression a dual isotope SPECT study. Psychiatry Res. 2008 162 (15):230-5.
  27. Joensuu M, Tomunen T, Saarinen PI et. al. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor beta CIT SPECT imaging. Psychiatry 2007 154 (2): 125-31
  28. Wolff LC et al. [Depression in HIV infection: prevalence, risk factors and management]. Rev Chilena Infectol. 2010 Feb;27(1):65-74. Epub 2010 Feb 3.
  29. Liu SS et al. Depression in patients with heart disease: the case for more trials. Future Cardiol. 2010b Jul;6(4):547-56.
  30. Morris R et al. Depression and anxiety screening after stroke: adherence to guidelines and future directions. Disabil Rehabil. 2011 Oct 17. [Epub ahead of print]
  31. Jayadevappa R et al. The burden of depression in prostate cancer. Psychooncology. 2011 Aug 12. doi: 10.1002/pon.2032. [Epub ahead of print]
  32. Stuart MJ et al. Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev. 2011 Oct 14. [Epub ahead of print]
  33. Hemmerle AM et al. Stress, depression and Parkinson's disease. Exp Neurol. 2011 Oct 6. [Epub ahead of print]
  34. Shibasaki M et al. [Functional homology between alcohol dependence and mood disorder]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2011 Jun;46(3):337-46.
  35. Stipcevic T et al. Platelet serotonin concentration and monoamine oxidase activity in hypothyroid patients. Horm Res. 2009;71(4):207-12. Epub 2009 Mar 4.
  36. Davis JD et al. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol. 2007 Mar;32(1):49-65.
  37. Chang KD et al. Differences in thyroid function between bipolar manic and mixed states. Biol Psychiatry. 1998 May 15;43(10):730-3.
  38. Kupka RW et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry. 2002 Feb 15;51(4):305-11.
  39. Cole DP et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002 Jan;159(1):116-21.
  40. Frye MA et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry. 1999 Dec;156(12):1909-14.
  41. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120-37.
  42. Parcells DA. Women's mental health nursing: depression, anxiety and stress during pregnancy.J Psychiatr Ment Health Nurs. 2010 Nov;17(9):813-20.
  43. Bloch M, Aharonov I, Ben Avi I, et al. Gonadal steroids and affective symptoms during in vitro fertilization: implication for reproductive mood disorders. Psychoneuroendocrinology. 2011 Jul;36(6):790-6.
  44. Sundermann EE, Maki PM, Bishop JR.A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition. Menopause. 2010 Jul;17(4):874-86.
  45. Kikuchi H, Nakatani Y, Seki Y, Yu X, Sekiyama T, Sato-Suzuki I, Arita H. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women.J Psychosom Obstet Gynaecol. 2010 Jun;31(2):83-9.
  46. Cubeddu A, Giannini A, Bucci F, Merlini S, Casarosa E, Pluchino N, Luisi S, Luisi M, Genazzani AR. Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Menopause. 2010 Mar;17(2):338-43.
  47. Zitzmann M. Testosterone and the brain. Aging Male. 2006 Dec;9(4):195-9.
  48. Delhez M et al. [Testosterone and depression in men aged over 50 years. Andropause and psychopathology: minimal systemic work-up]. Ann Endocrinol (Paris). 2003 Apr;64(2):162-9.
  49. Jankowska EA, Drohomirecka A, Ponikowska B, et al. Deficiencies in circulating testosterone and dehydroepiandrosterone sulphage, and depression in men with systolic chronic heart failure. Eur J Heart Fail. 2010 Sep;12(9):966-73.
  50. Zarrouf FA, Artz S, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009;15:289-305.
  51. Yehuda S et al. Essential fatty acids and the brain:from infancy to aging. Neurobiology of Aging. 2005; 26 (Suppl 1), 98–102.
  52. Faloon W. “Startling Findings About Vitamin D Levels in Life Extension® Members” Life Extension Magazine. January 2010.
  53. Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res 2010; 68:261-75.
  54. Wolkowitz OM et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. PLoS One. 2011a Mar 23;6(3):e17837.
  55. Kim MY et al. Leukocyte mitochondrial DNA (mtDNA) content is associated with depression in old women. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):e218-21. Epub 2010 Dec 14.
  56. Lee JW et al. Mitochondrial DNA copy number in peripheral blood is associated with cognitive function in apparently healthy elderly women. n Chim Acta. 2010 Apr 2;411(7-8):592-6. Epub 2010 Jan 28.
  57. Maes M, Mihaylova I, et al. Lower plasma coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009;30:462-9.
  58. Pettigrew JW, Levine J, et al. P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disorders 2000;4:61-6.
  59. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neruopsychopharmacol 2006;16:281-7.
  60. Malaguarnera M et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011 Jun;46(6):750-9. Epub 2011 Mar 28.
  61. Rossini M et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007 Mar-Apr;25(2):182-8.
  62. Chowanadisai W et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010 Jan 1;285(1):142-52. Epub 2009 Oct 27.
  63. Rucker R et al. Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev. 2009 Sep;14(3):268-77.
  64. Tachaparian E et al. Identification of transcriptional networks responding to pyrroloquinoline quinone dietary supplementation and their influence on thioredoxin expression, and the JAK/STAT and MAPK pathways. Biochem J. 2010 Aug 1;429(3):515-26.
  65. Bauerly K et al. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS One. 2011;6(7):e21779. Epub 2011 Jul 21.
  66. Zhang Y et al. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res. 2006 Jun 13;1094(1):200-6. Epub 2006 May 18.
  67. Zhang JJ et al. Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett. 2009 Oct 30;464(3):165-9. Epub 2009 Aug 20.
  68. Kemp DE et al. Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 2011 Jul 20. [Epub ahead of print]
  69. Ohaeri JU et al. Metabolic syndrome in severe mental disorders. Metab Syndr Relat Disord. 2011 Apr;9(2):91-8. Epub 2010 Oct 21.
  70. Tsao CW, Lin YS, et al. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:899-905.
  71. Craddock D, Thomas A. Cytokines and late-life depression. Essent Psychopharmacol 2006;7:42-52.
  72. O’Brien SM, Scully P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326-31.
  73. Cizza G et al. Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. Horm Metab Res. 2009 Aug;41(8):641-8. Epub 2009 Apr 30.
  74. Dantzer R et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011 Apr;36(3):426-36. Epub 2010 Oct 30.
  75. Christmas DM et al. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat. 2011;7:431-9. Epub 2011 Jul 13.
  76. Warner CH et al. Antidepressant Discontinuation Syndrome. Am Fam Physician. 2006 Aug 1;74(3):449-456.
  77. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: A meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754–62.
  78. Schneider C, Lovett E. Depression. In: Integrative Medicine. Rakel D (ed). Saunders Elsevier, Philadelphia, pp.78, 2007.
  79. Lisanby SH et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry. 2000 Jun;57(6):581-90.
  80. Calev A et al. ECT and non-memory cognition: a review. Br J Clin Psychol. 1995 Nov;34 ( Pt 4):505-15.
  81. Inoue K. [Cognitive-behavioral therapy for treatment-resistant depression]. Seishin Shinkeigaku Zasshi. 2010;112(11):1097-104.
  82. Hynninen MJ et al. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med. 2010 Jul;104(7):986-94. Epub 2010 Mar 25.
  83. Weisz JR et al. Cognitive-behavioral therapy versus usual clinical care for youth depression: an initial test of transportability to community clinics and clinicians. J Consult Clin Psychol. 2009 Jun;77(3):383-96.
  84. Freeman MP, Fava M, et al. Complementary and Alternative Medicine in major depressive disorder: the American psychiatric association task force report. J Clin Psychiatry 2010;71:669-81.
  85. Babyak M, Blumenthal JA, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000;62:633-8.
  86. Hoffman BM, Babyak MA, et al. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med 2011;73:127-33.
  87. Lam RW, Levitt AJ, et al. The Can-SAD study: a randomized controled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163:805-12.
  88. George MS, Lisanby SH, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder. Arch Gen Psychiatry 2010; 67:507-16.
  89. Schutter DJ. [Transcranial magnetic stimulation as a treatment for depression]. Tijdschr Psychiatr. 2011;53(6):343-53.
  90. McNamara RK et al. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 2008 Sep 30;160(3):285-99. Epub 2008 Aug 20.
  91. Lin, P., & Su, K. (2007). A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. Journal of Clinical Psychiatry, 68(7), 1056–1061.
  92. Tolmunen, T., Hintikka, J., Ruusunen, A., Voutilainen, S., Tanskanen, A., Valkonen, V. P., et al. (2004). Dietary folate and the risk of depression in Finnish middle-aged men. A prospective follow-up study. Psychotherapy and Psychosomatics, 73, 334–339.
  93. Sanchez-Villegas, A., Henriquez, P., Bes-Rastrollo, M., & Doreste, J. (2006). Mediterranean diet and depression. Public Health Nutrition, 9, 1104–1109.
  94. Fuller-Thomson E et al. The association between depression and thyroid disorders in a regionally representative Canadian sample. Psychol Health Med. 2011 Sep 26. [Epub ahead of print]
  95. Lojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord 2007;103:253-6.
  96. Fang Y et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol. 2011 Oct;31(5):638-42.
  97. Girdler SS et al. A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. Psychoneuroendocrinology. 2011 Sep 2. [Epub ahead of print]
  98. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci. 2002 Aug;16(3):445–53.
  99. Abadie JM, Wright B et al. Effect of dehydroepiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. The Obesity Research Program. Diabetes. 1993 May;42(5):662–9.
  100. Rabkin JG, McElhiney MC et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry. 2006 Jan;163(1):59–66.
  101. Schmidt PJ, Daly RC et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005 Feb;62(2):154–62.
  102. Barrett-Connor E, Von Muhlen DG et al. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab. 1999 Feb;84(2):573–7.
  103. Schweiger U, Deuschle M et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med. 1999 May;61(3):292–6.
  104. Giltay EJ, Tishova YA, et al. Effects of testosterone supplementation on depressive syptoms and sexual dysfunction in hypogonadal men with metabolic syndrome. J Sex Med 2010;7:2572-82.
  105. Shores MM, Kivlahan DR, et al. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70:1009-16.
  106. Pope HG Jr, Cohane GH et al. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry. 2003 Jan;160(1):105–11.
  107. Grigoriadis S, Kennedy SH. Role of estrogen in the treatment of depression. Am J Ther. 2002 Nov;9(6):503–9.
  108. Miller KJ, Conney JC et al. Mood symptoms and cognitive performance in women estrogen users and nonusers and men. J Am Geriatr Soc. 2002 Nov;50(11):1826–30.
  109. Schneider LS, Small GW et al. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry. 2001;9(4):393–9.
  110. Osterlund MK. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim Biophys Acta. 2010;1800:1136-44.
  111. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge? Biol Psychiatry. 1998 Nov 1;44(9):798–811.
  112. Rubinow DR, Schmidt PJ et al. Estrogen-serotonin interactions: Implications for affective regulation. Biol Psychiatry. 1998 Nov 1;44(9):839–50.
  113. Bethea CL, Pecins-Thompson M et al. Ovarian steroids and serotonin neural function. Mol Neurobiol. 1998 Oct;18(2):87-123. Review.
  114. Kendall DA, Stancel GM et al. The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J Neurosci. 1982 Mar;2(3):354–60.
  115. Barha CK and Galea LA. Influence of different estrogens on neuroplasticity and cognition in the hippocampus. Biochim Biophys Acta. 2010 Oct;1800(10):1056-67. Epub 2010 Jan 25.
  116. Vidailhet P. [Depressive recurrence: cognitive alterations and neuroplasticity]. Encephale. 2010 Dec;36 Suppl 5:S140-4.
  117. Bellipanni G, Bianchi P, et al. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol 2001;36:297-310.
  118. Serafty MA, Osborne D, et al. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010;25:132-42.
  119. Green B. Focus on agomelatine. Curr Med Res Opin 2011;27:745-9.
  120. Hickie IB et al. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011 Aug 13;378(9791):621-31. Epub 2011 May 17.
  121. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: Possible mechanisms and therapeutic value in major depression. Altern Med Rev. 2003 Nov;8(4):410–25.
  122. Bourre JM, Dumont O et al. Essentiality of omega 3 fatty acids for brain structure and function. World Rev Nutr Diet. 1991;66:103–17.
  123. Tanskanen A, Hibbeln JR, Hintikka J, et al. Fish Consumption, Depression, and Suicidality in a General Population. Arch Gen Psychiatry. 2001;58(5):512-13.
  124. Tiemeier, H., Van Tuijl, H. R., Hofman, A., Kiliaan, A. J., & Breteler, M. M. B. (2003). Plasma fatty acid composition and depression are associated in the elderly: The Rotterdam study. American Journal of Clinical Nutrition, 78(1), 40–46.
  125. Puri BK, Counsell SJ et al. Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract. 2001 Oct;55(8):560–3.
  126. Nemets H, Nemets R et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006 Jun;163(6):1098-100.
  127. Williams AL, Katz D et al. Do essential fatty acids have a role in the treatment of depression? J Affect Disord. 2006 Jul;93(1-3):117-23. Epub 2006 May 2.
  128. Burr ML, Fehily AM et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–61.
  129. Singh RB, Niaz MA et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival—4. Cardiovasc Drugs Ther. 1997 Jul;11(3):485–91.
  130. Nadler JL, Rude RK. Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 1995;24:623-41.
  131. Whittle N et al. Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids. 2011 Apr;40(4):1231-48. Epub 2011 Feb 11.
  132. Eby GA, Eby KL. Magnesium for treatment-resistant depression: a review and hypothesis. Medical Hypotheses 2010;74(4):649-60.
  133. Slutsky L et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan 28;65(2):165-77.
  134. Abumaria N et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011 Oct 19;31(42):14871-81.
  135. Hausenblas HA, Heekin K, Mutchie HL, Anton S. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med. Jul 2015;13(4):231-240.
  136. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human psychopharmacology. Nov 2014;29(6):517-527.
  137. Dorri SA, Hosseinzadeh H, Abnous K, Hasani FV, Robati RY, Razavi BM. Involvement of brain-derived neurotrophic factor (BDNF) on malathion induced depressive-like behavior in subacute exposure and protective effects of crocin. Iranian journal of basic medical sciences. Oct 2015;18(10):958-966.
  138. De Monte C, Carradori S, Chimenti P, et al. New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies. European journal of medicinal chemistry. Jul 23 2014;82:164-171.
  139. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Progress in neuro-psychopharmacology & biological psychiatry.Mar 30 2007;31(2):439-442.
  140. Shahmansouri N, Farokhnia M, Abbasi SH, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord. Feb 2014;155:216-222.
  141. Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. J Affect Disord. Mar 15 2015;174:51-56.
  142. Mazidi M, Shemshian M, Mousavi SH, et al. A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. Journal of complementary & integrative medicine. Jun 1 2016;13(2):195-199.
  143. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine: international journal of phytotherapy and phytopharmacology. Nov 2006;13(9-10):607-611.
  144. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy research: PTR. Feb 2005;19(2):148-151.
  145. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of sex & marital therapy. Fall 1997;23(3):176-194.
  146. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psycho+pharmacol. Jan 2013;28(1):54-60.
  147. Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. Oct 2012;223(4):381-388.
  148. Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. The Cochrane database of systematic reviews.2013;6:Cd001396.
  149. Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG: an international journal of obstetrics and gynaecology. Mar 2008;115(4):515-519.
  150. Murphy SE, Longhitano C et al. Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers. Psychopharmacology (Berl). 2006 Jul;187(1):121–30.
  151. Kaye WH et al. Effects of acute tryptophan depletion on mood in bulimia nervosa. Biol Psychiatry. 2000 Jan 15;47(2):151-7.
  152. Booij L, Swenne CA, et al. Tryptophan depletion affects heart rate variability and impulsivity in remitted depressed patients with a history of suicidal ideation. Biol Psychiatry 2006;60:507-14.
  153. Neumeister A, Turner EH, et al. Effects of tryptophan depletion vs. catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998;55:524-30.
  154. Papakostas GI, Mishoulon D, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind randomized clinical trial. Am J Psychiatry 2010; 167:942-8.
  155. Alpert JE, Papakostas G, et al. S-adenosyl-methionine (SAMe) as an adjunct for reistant major depressive disorder. J of Clin Psycopharmacol 2004;24:661-4.
  156. Alpert, J. E., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2000). Nutrition and depression: Focus on folate. Nutrition, 16, 544–546.
  157. Fava M et al. Folate, vitamin B12, and homocysteine in major depressive disorder. American Journal of Psychiatry, 1997 Mar;154(3), 426–428.
  158. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord. 2000 Nov;60(2):121–30.
  159. Morris MS, Fava M et al. Depression and folate status in the US population. Psychother Psychosom. 2003 Mar;72(2):80–7.
  160. Willems FF et al. Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol. 2004 Mar;141(5):825-30. Epub 2004 Feb 9.
  161. Lewis SJ et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry. 2006 Apr;11(4):352-60.
  162. Hector, M., & Burton, J. R. (1988). What are the psychiatric manifestations of vitamin B12 deficiency? Journal of the American Geriatrics Society, 36(12), 1105–1112.
  163. Sun, Y., Lai, M., & Lu, C. (2005). Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurologica Taiwanica, 14(2), 48–54.
  164. Bertoglio K, James JS, et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med 2010;16:555-60.
  165. Baldewicz, T. T., Goodkin, K., Blaney, N. T., Shor-Posner, G., Kumar, M., Wilkie, F. L., et al. (2000). Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression in bereaved HIV-1+ and HIV-1- homosexual men. Journal of Psychosomatic Research, 48(2), 177–185.
  166. Adams PW, Rose DP, et al. Effect of pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraceptives. Lancet 1973;1:897-904.
  167. Merete C et al. Vitamin B6 is associated with depressive symptomatology in Massachusetts elders. J Am Coll Nutr. 2008 Jun;27(3):421-7.
  168. Lucas M et al. Coffee, caffeine, and risk of depression among women. Arch Intern Med. 2011 Sep 26;171(17):1571-8.
  169. Ruusunen A et al. Coffee, tea and caffeine intake and the risk of severe depression in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Public Health Nutr. 2010 Aug;13(8):1215-20. Epub 2010 Apr 1.
  170. Tunnicliffe JM et al. Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats. Appl Physiol Nutr Metab. 2011 Oct;36(5):650-9. Epub 2011 Oct 6.
  171. Zhang LT et al. [Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Jun;33(3):281-6.
  172. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007 Nov-Dec;35(6):900-8.
  173. McCarty MF et al. Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression--an adjuvant role for chromium picolinate? Med Hypotheses. 1994 Oct;43(4):247-52.
  174. MacLeod MN, Gaynes BN, et al. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry1999;60:237-40.
  175. Davidson JR, Abraham K, et al. Efectiveness ofchromium in atypical depression. Biol Psychiatry 2003;53:261-4.
  176. Docherty JP, Sack DA, et al. A double-blind, placebo controlled, exploratory trial of chromium picolinate inatypical depression: effect on carbohydrate craving. 2005;11:302-14.
  177. Berk M, Dean O, et al. The efficacy of N-acetycysteine as an adjunctive treatment in bipolar depression: an open label trial. J Afect Disord 2011;Jun 28[Epub ahead of print].
  178. Jin HY, Joung SJ, et al. The effect of alpha-lipoic acid on sumptoms and skin blood flow in diabetic neuropathy. Diabet Med 2007;24:1034-8.
  179. Hawkes WC, Hornbostel L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 1996;39:121-8.
  180. Pathak L, Agrawal Y, Dhir A. Natural polyphenols in the management of major depression. Expert opinion on investigational drugs. Jul 2013;22(7):863-880.
  181. Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. Journal of psychopharmacology (Oxford, England). Dec 2012;26(12):1512-1524.
  182. Zhang L, Luo J, Zhang M, Yao W, Ma X, Yu SY. Effects of curcumin on chronic, unpredictable, mild, stress-induced depressive-like behaviour and structural plasticity in the lateral amygdala of rats. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). Jan 9 2014:1-14.
  183. Zhao X, Wang C, Zhang JF, Liu L, Liu AM, Ma Q, . . . Xu Y. Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABA receptor. Psychopharmacology. Dec 3 2013.
  184. Finan PH, Smith MT. The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism. Sleep medicine reviews. Jun 2013;17(3):173-183.
  185. Ong KS, Keng SB. The biological, social, and psychological relationship between depression and chronic pain. Cranio : the journal of craniomandibular practice. Oct 2003;21(4):286-294.
  186. Arora V, Kuhad A, Tiwari V, Chopra K. Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology. Nov 2011;36(10):1570-1581.
  187. Jiang H, Wang Z, Wang Y, Xie K, Zhang Q, Luan Q, . . . Liu D. Antidepressant-like effects of curcumin in chronic mild stress of rats: involvement of its anti-inflammatory action. Progress in neuro-psychopharmacology & biological psychiatry. Dec 2 2013;47:33-39.
  188. Bergman J, Miodownik C, Bersudsky Y, Sokolik S, Lerner PP, Kreinin A, . . . Lerner V. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clinical neuropharmacology. May-Jun 2013;36(3):73-77.
  189. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors (Oxford, England). Jan-Feb 2013;39(1):2-13.
  190. Noorafshan A, Ashkani-Esfahani S. A review of therapeutic effects of curcumin. Current pharmaceutical design. 2013;19(11):2032-2046.
  191. Whiskey E, Taylor D. A review of the adverse effects and safety of noradrenergic antidepressants. Journal of psychopharmacology (Oxford, England). Aug 2013;27(8):732-739.
  192. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Molecular psychiatry. Dec 2012;17(12):1186-1193.
  193. Asher GN, Spelman K. Clinical utility of curcumin extract. Alternative therapies in health and medicine. Mar-Apr 2013;19(2):20-22.
  194. Nangia M, Syed W et al. Efficacy and safety of St. John’s wort for the treatment of major depression. Public Health Nutr. 2000 Dec;3(4A):487–94.
  195. Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John’s wort extract WS 5770 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6.
  196. Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxitine: a randomized controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000:15:61-8.
  197. Szegedi A, Kohnen R et al. Acute treatment of moderate to severe depression with Hypericum extract WE 5570 (St John’s wort): Randomized controlled double-blind non-inferiority trial versus paroxetine. BMJ 2005;330:503.
  198. Butterweck V. Mechanism of action of St John’s wort in depression: what is known? CNS Drugs 2003;17:539-62.
  199. Can OD et al. Effects of Insulin and St. John's Wort Treatments on Anxiety, Locomotory Activity, Depression, and Active Learning Parameters of Streptozotocin-Diabetic Rats. Planta Med. 2011 Aug 19. [Epub ahead of print]
  200. Kim HL, Streltzer J et al. St. John’s wort for depression: A meta-analysis of well-defined clinical trials. J Nerv Ment Dis. 1999 Sep;187(9):532–8.
  201. Linde K, Ramirez G et al. St John’s wort for depression: An overview and meta-analysis of randomised clinical trials. BMJ. 1996 Aug 3;313(7052):253–8.
  202. Namri A, Mizoue T, et al. Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season. Eur J Clin Nutr 2009;63:1444-7.
  203. Shipowick CK, Moore CB, et al. Vitamin D and depressive symptoms in women during the winter: a pilot study. Appl Nurs Res 2009;22:221-5.
  204. May HT, Bair TL, et al. Association of vitamin D levels with incident depression among a general cardiovascular population. Am Heart J 2010;159:1037-43.
  205. Jorde R, Sneve M, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med 2008;264:599-609.
  206. Nowak G, Szewczyk B. Mechanisms contributing to antidepressant zinc actions. Pol J Pharmacol. 2002 Nov;54(6):587–92.
  207. Levenson CW. Zinc: the new antidepressant? Nutrition Reviews 2006;64:39-42.
  208. Maes M, D’Haese PC et al. Hypozincemia in depression. J Affect Disord. 1994 Jun;31(2):135–40.
  209. Maes M, Vandoolaeghe E et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry. 1997 Sep 1;42(5):349–58.
  210. McLoughlin IJ, Hodge JS. Zinc in depressive disorder. Acta Psychiatr Scand. 1990 Dec;82(6):451–3.
  211. Nowak G, Schlegel-Zawadzka M. Alterations in serum and brain trace element levels after antidepressant treatment: Part I. Zinc. Biol Trace Elem Res. 1999 Jan;67(1):85–92.
  212. Nowak G, Siwek M, et al. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-contolled study. Pol J Pharmacol 2003;55:1143-7.
  213. Kroczka B, Branski P et al. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001 May 15;55(2):297–300.
  214. Sairanen M, Lucas G, et al. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation and survival in the adult dentate gyrus. J Neurosci 2005;25:1089-94.
  215. Levine J, Barak Y et al. Double blind controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:1084-6.
  216. Chengappa KN, Levine J, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2:46-55.
  217. Evins, A. E., Demopulos, C., Yovel, I., Culhane, M., Ogutha, J., Grandin, L. D., et al. (2006). Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disorders, 8, 168–174.
  218. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical therapeutics.May 1 2015;37(5):984-995.
  219. Foster JA, Lyte M, Meyer E, Cryan JF. Gut microbiota and brain function: An evolving field in neuroscience. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP).Oct 4 2015.
  220. Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun.Jan 2010;24(1):9-16.
  221. Forsythe P, Kunze WA. Voices from within: gut microbes and the CNS. Cellular and molecular life sciences: CMLS.Jan 2013;70(1):55-69.
  222. Dinan TG, Cryan JF. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology.Sep 2012;37(9):1369-1378.
  223. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci.2012;13(10):701-712.
  224. Sanders ME. Probiotics: Definition, Sources, Selection, and Uses. Clinical Infectious Diseases.February 1, 2008 2008;46(Supplement 2):S58-S61.
  225. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences of the United States of America. Sep 20 2011;108(38):16050-16055.
  226. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut.Nov 2007;56(11):1522-1528.
  227. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. The British journal of nutrition. Mar 2011;105(5):755-764.
  228. Arseneault-Breard J, Rondeau I, Gilbert K, Girard SA, Tompkins TA, Godbout R, Rousseau G. Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. The British journal of nutrition.Jun 2012;107(12):1793-1799.
  229. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. Jul-Aug 2011;2(4):256-261.
  230. Calcaterra NE, Barrow JC. Classics in chemical neuroscience: diazepam (valium). ACS chemical neuroscience.Apr 16 2014;5(4):253-260.